Arecor Therapeutics PLC (AIM:AREC) is “well positioned for significant future growth and success”, according to chief executive Sarah Howell, as the company reported strong progress across its pipeline, particularly in diabetes care and oral peptide delivery.
In full-year results published on Tuesday, the Cambridge-based drug developer highlighted key clinical milestones for AT278, its ultra-concentrated insulin candidate, and early data supporting a new platform for orally delivered peptides. Discussions for a strategic partnership for AT278 are said to be progressing, following positive Phase I trial results in patients with Type 2 diabetes.
Alongside this, Arecor has launched a research collaboration with TRx Biosciences to develop a novel oral peptide delivery system, initially targeting glucagon-like peptide-1 (GLP-1) receptor agonists.
Early formulation work has shown promise, with animal studies underway to optimise absorption.
The company’s Arestat drug enhancement platform continues to generate revenue through licensing deals, including royalties from the AT220 biosimilar product and a separate agreement with Sanofi.
For 2024, revenue rose to £5.1 million from £4.6 million. Reflecting heavy investment in R&D activities, the operating loss before exceptional items was £7.4 million.
Arecor completed a £6.4 million fundraise during the year, backed by two international life sciences investors.